4D pharma plc (AIM: DDDD) announces the effective merger with Longevity Acquisition Corporation, enhancing its operational capabilities in developing Live Biotherapeutic products. The merger provides 4D with $14.8 million in cash, and 4D ADSs will begin trading on NASDAQ under 'LBPS.' The private placement with Merck Sharp & Dohme Corp. raised an additional $1 million, totaling about $25 million raised thus far. Following the merger, 4D is strategically positioned with an enhanced cash base of $40 million to advance its clinical programs in the microbiome sector.
4D pharma plc (Nasdaq: LBPS; AIM: DDDD) announced the completion of its merger with Longevity Acquisition Corporation. 4D's American Depositary Shares (ADSs) will begin trading on Nasdaq today under the ticker LBPS, while warrants are expected to trade under LBPSW. Following the merger, Longevity's shares ceased trading on Nasdaq. 4D pharma specializes in Live Biotherapeutics, a novel class of drugs derived from the microbiome, and has several clinical programs in progress, including studies involving MRx0518 and MRx-4DP0004 for various conditions.